Hierarchical Modeling of Activation Mechanisms in the ABL and EGFR Kinase Domains: Thermodynamic and Mechanistic Catalysts of Kinase Activation by Cancer Mutations by Dixit, Anshuman & Verkhivker, Gennady M.
Hierarchical Modeling of Activation Mechanisms in the
ABL and EGFR Kinase Domains: Thermodynamic and
Mechanistic Catalysts of Kinase Activation by Cancer
Mutations
Anshuman Dixit
1, Gennady M. Verkhivker
1,2,3*
1Graduate Program in Bioinformatics and Center for Bioinformatics, The University of Kansas, Lawrence, Kansas, United States of America, 2Department of
Pharmaceutical Chemistry, School of Pharmacy, The University of Kansas, Lawrence, Kansas, United States of America, 3Department of Pharmacology, University of
California at San Diego, La Jolla, California, United States of America
Abstract
Structural and functional studies of the ABL and EGFR kinase domains have recently suggested a common mechanism of
activation by cancer-causing mutations. However, dynamics and mechanistic aspects of kinase activation by cancer
mutations that stimulate conformational transitions and thermodynamic stabilization of the constitutively active kinase
form remain elusive. We present a large-scale computational investigation of activation mechanisms in the ABL and EGFR
kinase domains by a panel of clinically important cancer mutants ABL-T315I, ABL-L387M, EGFR-T790M, and EGFR-L858R. We
have also simulated the activating effect of the gatekeeper mutation on conformational dynamics and allosteric interactions
in functional states of the ABL-SH2-SH3 regulatory complexes. A comprehensive analysis was conducted using a hierarchy
of computational approaches that included homology modeling, molecular dynamics simulations, protein stability analysis,
targeted molecular dynamics, and molecular docking. Collectively, the results of this study have revealed thermodynamic
and mechanistic catalysts of kinase activation by major cancer-causing mutations in the ABL and EGFR kinase domains. By
using multiple crystallographic states of ABL and EGFR, computer simulations have allowed one to map dynamics of
conformational fluctuations and transitions in the normal (wild-type) and oncogenic kinase forms. A proposed multi-stage
mechanistic model of activation involves a series of cooperative transitions between different conformational states,
including assembly of the hydrophobic spine, the formation of the Src-like intermediate structure, and a cooperative
breakage and formation of characteristic salt bridges, which signify transition to the active kinase form. We suggest that
molecular mechanisms of activation by cancer mutations could mimic the activation process of the normal kinase, yet
exploiting conserved structural catalysts to accelerate a conformational transition and the enhanced stabilization of the
active kinase form. The results of this study reconcile current experimental data with insights from theoretical approaches,
pointing to general mechanistic aspects of activating transitions in protein kinases.
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Introduction
Protein kinase genes are signaling switches with a conserved
catalytic domain that phosphorylate protein substrates and thereby
play a critical role in cell signaling [1–5]. As a result, many protein
kinases have emerged as important therapeutic targets for
combating diseases caused by abnormalities in signal transduction
pathways, especially various forms of cancer. A large number of
protein kinase crystal structures in the free form and complexes
with various inhibitors have been determined, resulting in the
growing wealth of structural information about the kinase catalytic
domain [6–9]. The crystal structures have revealed considerable
structural differences between closely related active and highly
specific inactive kinase forms [10–24]. Conformational plasticity
and diversity of crystal structures of the ABL [10–21] and EGFR
kinase domains [22–24] have demonstrated the existence of active,
inactive, Src-like inactive and intermediate conformational forms.
Conformational transitions and dynamic equilibrium between
these distinct conformational states are important characteristics of
the kinase regulation and recognition by other molecules [25–28].
Evolutionary analysis of the functional constraints acting on
eukaryotic protein kinases (EPKs) demonstrated that protein
kinase mechanisms may have evolved through elaboration of a
simple structural component that included the HxD-motif
adjoining the catalytic loop, the F-helix, an F-helix aspartate,
and the catalytically critical Asp-Phe-Gly (DFG) motif from the
activation loop. This computational analysis showed how
distinctive structural elements of the kinase core may be linked
with the conformational changes of the DFG motif in kinase
regulation [29]. A surface comparison of crystal structures for
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conserved residues that are most sensitive to activation [30].
According to the proposed model, critical features of the common
activation mechanism may include a dynamic assembly of the
‘‘hydrophobic spine’’ motif and the formation of specific salt
bridges that can collectively provide coordination of the kinase
lobes during activation process [30,31]. These illuminating studies
have demonstrated that protein kinase function may be controlled
by a dynamic assembly of spatially distributed conserved residues
important in regulation of allosteric signaling pathways. In a
subsequent study, it was proposed that the F-helix of the kinase
domain may act as a central scaffold in the assembly of active
protein kinase forms by anchoring the hydrophobic regulatory
spine (R-spine) and a second functional cluster termed catalytic
spine (C-spine) [32].
Abnormal activation of protein kinases is among major causes of
human diseases, especially various cancers. Resequencing studies
of kinase coding regions in tumors have revealed that a small
number of kinase mutations contribute to tumor formation, while
the majority are neutral mutational byproducts of somatic cell
replication [33–35]. Mutations in protein kinases are implicated in
many cancers [36] and often exemplify the phenomenon of
oncogene addiction [37,38], whereby structural effects of onco-
genic mutations confer a selective advantage for tumor formation
during somatic cell replication. The dominant oncogenes that
confer the oncogene addiction effect include ABL, EGFR,
VEGFR, BRAF, RET, and MET kinase genes [38]. The
dependence of chronic myeloid leukemia (CML) on the translo-
cated BCR-ABL kinase is correlated with dramatic responses to
small molecule inhibitors. A large number of diverse point
mutations that impair the binding of Imatinib (Gleevec) to ABL
have been described [39–41], suggesting that some drug resistant
mutations could exist before treatment, and may contribute to
tumorigenesis. The profound selectivity of Imatinib at inhibiting a
small group of protein tyrosine kinases is achieved by the high
precision with which this inhibitor can recognize the inactive
conformation of the activation loop in ABL, KIT and PDGFR
kinases [42,43]. Structurally conserved gate-keeper mutation ABL-
T315I is a dominant cancer-causing alteration, leading to the most
severe Imatinib resistance by favoring the active form of the ABL
kinase. Subsequently, a series of rationally designed analogs of
Imatinib based on the core scaffold were shown to recognize a
broader spectrum of inactive kinase conformations and inhibit
with equal potency both ABL and C-Src kinases [44]. Inhibitors
that bind to the inactive conformation face weaker competition
from cellular ATP and may act by shifting equilibrium between
conformational states in a way that prevents kinase activation,
rather than by inhibiting kinase activity directly.
A spectrum of lung cancer-derived EGFR mutations can induce
oncogenic transformation by leading to constitutive kinase activity
and confer markedly different degrees of sensitivity to EGFR
inhibitors [45–47]. Similarly, EGFR-T790M mutant could cause
resistance to Gefitinib and Erlotinib drugs in the treatment of lung
cancer [48,49]. Importantly, these mutations can promote
oncogenic activation, uncontrolled cell proliferation and tumori-
genesis even in the absence of the selective pressure from the
kinase inhibitors. An activating mutation in the activation loop of
the EGFR kinase domain, L858R (also identified as Leu834 in a
different numbering of the EGFR sequence) is among most
frequent mutations in lung cancer, amounting to more than 40%
of EGFR mutations in this cancer category [45–47]. While
T790M has only a modest effect on EGFR function, a tandem of
T790M and L858R mutations can result in a dramatic
enhancement of EGFR activity [50]. The crystal structures of
EGFR-L858R, EGFR-T790M [51–53] and ABL-T315I mutants
[54,55] have shown that these cancer-causing modifications could
stabilize the active kinase form. Recent structural and mutagenesis
investigations have asserted a common activating nature of the
gatekeeper mutations in c-ABL, c-Src, and EGFR and PDGFR
kinases [56]. Moreover, mutations of the gatekeeper residues to
smaller amino acids and pharmacological intervention by the
inhibitor binding, which interfere with the structural integrity of
the hydrophobic spine, could effectively abrogate the kinase
activity. Conversely, substitutions of the gatekeeper residues with
bulkier modifications, that strengthen the hydrophobic spine, tend
to correlate with the enhanced oncogenic activation of ABL and
EGFR kinases [56]. These studies have proposed a mechanism of
activation in which stabilization of the hydrophobic regulatory
spine may promote shift of the kinase equilibrium towards the
constitutively active kinase form, and thus have a dramatic effect
on the regulation of the enzyme.
Crystallographic analysis may not capture the complete
ensemble of protein kinase conformations available in solution
under physiological conditions. NMR spectroscopy techniques can
effectively complement X-ray studies by providing a more
adequate characterization of conformational ensembles and
dynamics of transitions between different kinase states [57,58].
The first NMR characterization of ABL kinase in complexes with
various inhibitors has been recently reported [57]. This study has
detected microsecond to millisecond motions of the activation loop
seen in both the active and inactive states, suggesting that this
mobility may be an intrinsic structural requirement for enabling
conformational transitions between alternative kinase conforma-
tions. Hydrogen exchange mass spectrometry (HX MS) has been
applied to investigate conformational dynamics of ABL upon
T315I mutation [58]. The effect of ABL-T315I mutation
manifested not only in the local conformational disturbances near
site of mutation, but also influenced protein flexibility in remote
regions of the SH3 domain. Hence, allosteric interactions and
inter-domain communication of ABL regulatory complexes could
Author Summary
Mutations in protein kinases are implicated in many
cancers, and an important goal of cancer research is to
elucidate molecular effects of mutated kinase genes that
contribute to tumorigenesis. We present a comprehensive
computational study of molecular mechanisms of kinase
activation by cancer-causing mutations. Using a battery of
computational approaches, we have systematically inves-
tigated the effects of clinically important cancer mutants
on dynamics of the ABL and EGFR kinase domains and
regulatory multi-protein complexes. The results of this
study have illuminated common and specific features of
the activation mechanism in the normal and oncogenic
forms of ABL and EGFR. We have found that mutants with
the higher oncogenic activity may cause a partial
destabilization of the inactive structure, while simulta-
neously facilitating activating transitions and the enhanced
stabilization of the active conformation. Our results
provided useful insights into thermodynamic and mech-
anistic aspects of the activation mechanism and highlight-
ed the role of structurally distinct conformational states in
kinase regulation. Ultimately, molecular signatures of
activation mechanisms in the normal and oncogenic states
may aid in the correlation of mutational effects with
clinical outcomes and facilitate the development of
therapeutic strategies to combat kinase mutation-depen-
dent tumorigenesis.
Computational Modeling of Protein Kinases
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playing a major role in the kinase regulation in solution.
Computational studies have begun to investigate a molecular
basis of protein kinase function and the structural effects of
activating mutations, which may ultimately control the activity
signatures of cancer drugs and determine the scope of drug
resistance mutations [59,60]. A molecular mechanism of long-
range, allosteric conformational activation of Src tyrosine kinases
has been proposed by using a combination of experimental
enzyme kinetics and nonequilibrium molecular dynamics simula-
tions [61,62]. Atomistic simulations of large-scale allosteric
conformational transitions of adenylate kinase have suggested a
population-shift mechanism upon inhibitor binding [63]. Coarse-
grained and all-toms modeling using structural connectivity
mapping have allowed to characterize a collective dynamics of
conformational transitions between the inactive and active states of
the Src kinase [64–67]. Atomistic dynamics of the ‘‘open-to-
closed’’ movement of the cyclin-dependent kinase 5 (CDK5) has
been recently studied using a metadynamics sampling approach,
revealing a two-step molecular mechanism and the formation of
functionally important intermediates [68]. Molecular dynamics
(MD) simulations of ABL kinase and Imatinib-binding kinetics
assays have proposed that a protonation-dependent switch in the
DFG motif from the activation loop may allow the kinase to access
multiple conformations facilitating nucleotide binding and release
cycles [69]. Targeted molecular dynamics (TMD) simulations have
attempted to explore conformational transitions in the activation
loop of the c-Kit kinase domain [70]. Most recently, conforma-
tional dynamics of the EGFR kinase domain studied by TMD
simulations has suggested that formation of the hydrophobic spine
and salt bridges may be important in the activation process [71].
Computational studies of protein kinases have elucidated thermo-
dynamic factors of kinase activation, suggesting that cancer
mutations with the higher oncogenic activity may have the greater
destabilization effect on the inactive kinase structure [72,73].
These studies have suggested that the conserved topology of the
protein kinase fold could preserve global dynamics in the normal
and oncogenic forms, yet allowing for functionally important local
and allosteric conformational changes caused by mutations. The
basic mechanistic features of the protein kinase dynamics and
activation mechanisms may be interpreted using a conformational
selection model [74–77] and the energy landscape perspective
[74–80] of protein folding and binding. This theoretical
framework implies an ensemble of preexisting multiple conforma-
tional states on the underlying energy landscape, with the
mutations (or binding partners) shifting the energy landscape
and the relative populations of accessible states towards function-
ally relevant complexes [74–77]. An important role of conforma-
tional selection mechanisms has recently gained further promi-
nence [81], suggesting a broad applicability of this model in
explaining dynamic effects for a variety of biological systems [82–
85].
It was recently proposed that evolution may have preserved
protein flexibility features that retain the ability of kinases to
fluctuate normally between active and inactive states. In contrary,
cancer kinase mutations may result in the increased conforma-
tional space to be explored in the inactive state [72,73].
Thermodynamic and mechanistic effects of cancer mutations
may manifest in a preferential shifting of the landscape equilibrium
and altering of the accessible conformational space for deleterious
mutants through either local or allosteric-based dynamic changes.
A similar energy landscape-based framework for predicting the
effects of mutations on protein dynamics and binding was
successfully employed for allostery-based rescue mutant design in
a tumor suppressor protein [86] and studies of molecular evolution
of affinity and flexibility in the immune system [87,88].
Despite recent progress in computational and experimental
studies of protein kinases, a quantitative understanding of
thermodynamic and mechanistic catalysts of kinase activation by
cancer mutations is still lacking. In this study, we have embarked
on a detailed computational analysis of activation mechanisms in
the ABL and EGFR kinase domains using homology modeling,
MD simulations, protein stability analysis, TMD simulations and
molecular docking. A comparative analysis has been conducted
based on computational modeling of the wild type (WT) ABL and
EGFR kinase domains as well as a panel of clinically important
cancer mutants ABL-T315I, ABL-L387M, EGFR-T790M, and
EGFR-L858R. We have also simulated the effect of the gatekeeper
ABL-T315I mutation on conformational dynamics and allosteric
interactions in the ABL-SH2-SH3 regulatory complexes. In
support of the experimental hypotheses, our results have suggested
potential thermodynamic and mechanistic catalysts of the ABL
and EGFR kinase activation that may collectively accelerate
conformational transitions and result in the enhanced stabilization
of the active kinase form. We have also proposed a multi-stage
mechanistic model of the activation process that includes a series
of cooperative transitions resulting in the formation of key
intermediate states that are characterized by a rapid assembly of
the hydrophobic spine and subsequent stabilization of the Src-like
structures. Broadly, the results of study may reconcile current
experimental data with the insights from computational approach-
es, pointing to general mechanistic aspects of activating transitions
in protein kinases.
Results/Discussion
Conformational landscapes of the ABL (Figure S1) and EGFR
kinase domains (Figure S2) are characteristically marked by the
presence of structurally different protein forms with a diverse
arrangement of the activation loop seen in the inactive, Src-like
inactive, and active states. A conserved K271-E286 salt bridge is
present in the Imatinib-bound, inactive form (Figure S1 D) and
the active form of ABL (Figure S1 F), while it is conspicuously
absent in the Src-like inactive structure (Figure S1 E). The
analogous conserved salt bridge K745-E762 is formed in the active
EGFR conformation, but is dismantled in the Src/Cdk-like
inactive conformation (Figure S2 D–F). The crystal structures
of the ABL-T315I, EGFR-L858R, and EGFR-T790M mutants
adopted the active kinase conformation. Moreover, a crystallo-
graphic analysis of EGFR-WT, EGFR-L858R, and EGFR-
T790M indicated that activation of the kinase domain by cancer
mutations should instigate a large conformational transition from
the otherwise thermodynamically stable Src/Cdk-like inactive
conformation [24]. Hence, structural effects of ABL and EGFR
oncogenic mutations should lead to disruption of the autoinhibi-
tory interactions in the inactive kinase conformation and promote
a large conformational change of the activation loop.
Homology Modeling of the ABL and EGFR Mutants
An important initial insight into structural effects of activating
mutations was obtained from homology modeling of the conserved
gatekeeper mutants ABL-T315I and EGFR-T790M. Structural
analysis of ABL-T315I was attempted from the Imatinib-bound
inactive and Src-like inactive conformations. Similarly, homology
refinement of EGFR-T790M was carried out using the Src/Cdk-
like inactive EGFR conformations. The predicted structural
models conform closely to the crystallographic conformations of
the activation loop in the mutant structures within the root mean
Computational Modeling of Protein Kinases
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noting that the target conformations of the activation loop in the
mutant crystal structures assume the active form and were vastly
different (RMSD ,8A ˚–10A ˚) from the starting conformations
corresponding to the Src-like kinase state. Consequently, homol-
ogy modeling of mutational effects in the ABL and EGFR kinase
domains is rather challenging, albeit at a high sequence identity.
While homology refinement could not accurately reproduce
structural changes in the remote peripheral regions of the N-
terminal and C-terminal lobes, simulations were capable of
depicting the correct repositioning of the functionally important
P-loop, aC-helix and the activation loop (Figure 1). A close
structural inspection of the predicted ABL-T315I (Figure S3A)
and EGFR-T790M models (Figure S3B) revealed a specific
intermediate position of the Phe residue in the DFG motif that was
favored by the enhanced hydrophobic interactions with the
respective gatekeeper residue. Interestingly, while one copy of
the EGFR-T790M crystal structure was in the active state with the
characteristic ‘‘DFG-in’’ conformation, the second molecule
displayed a rather unique intermediate DFG conformation [52].
The DFG conformation in the predicted model of EGFR-T790M
closely overlapped with the one observed in the second molecule of
the EGFR-T790M crystal structure. A convergent structural effect
of the ABL-T315I and EGFR-T790M mutants (Figure S3C) seen
in the predicted models may have functional relevance in
facilitating conformational transition of the activation loop. The
bulkier mutant residues at the gatekeeper position may unlock the
DFG motif from its autoinhibitory conformation by strengthening
the hydrophobic interactions with the Phe residue in the
intermediate conformation. A specific DFG conformation, re-
cruited by the mutated gatekeeper residues, may act as a
conformational trigger in facilitating transition from the inactive
DFG-out to the active DFG-in state. The proposed structural
mechanism may thus initiate the disruption of the autoinhibitory
interactions and cause imbalance in the dynamic equilibrium
between inactive and active conformational states regulating
kinase activity. Hence, homology modeling of the ABL-T315I
and EGFR-T790M mutants could provide an initial insight into
molecular basis of activation by cancer mutations.
Homology refinement successfully reconstructed the active
crystallographic form of EGFR-L858R (pdb entry 2ITT)
(Figure 2A). A considerable conformational rearrangement in
the activation loop was predicted within RMSD=1.9 A ˚–2.0 A ˚
from the mutant crystal structure (Figure 2B). Moreover,
homology refinement correctly reproduced coordinated structural
changes of the activation loop and aC-helix (Figure 2A). The
ability of homology modeling refinement to reproduce a large
conformational change in EGFR-L858R may be partly attributed
to a considerable incompatibility of Arg858 with the Src/Cdk-like
inactive EGFR structure. In agreement with the assertion
originally made by Kuriyan and coworkers [24], a local
hydrophobic environment seemed to disfavor a polar side-chain
of EGFR-L858R in the Src/Cdk-like inactive structure, and this
may have facilitated a transition to a different local minimum
corresponding to the active kinase form. A close inspection of the
predicted structural model indicated that important interactions
formed in the crystal structure of EGFR-L858R could be
adequately reproduced, including a stable K745-E762 ion pair,
known as a critical attribute of the active kinase form (Figure 2C).
MD Simulations of the ABL/EGFR Kinase Domains and
Protein Stability Analysis
MD simulations of the ABL and EGFR kinase domains were
performed to address the following objectives: (a) to determine
whether thermal motions in structurally different conformational
states of ABL and EGFR may tolerate structural impact of
activating mutations; (b) to study equilibrium dynamics of the ABL
and EGFR kinase domain in the normal and oncogenic forms; and
(c) to investigate the impact of activating mutations on the
thermodynamic stability of structurally different conformational
states of ABL and EGFR. MD trajectories of the ABL kinase
domain (Figures 3–5) and EGFR kinase domain (Figures 6,7)
displayed important similarities and differences in the equilibrium
profile of the WT and mutant forms. The RMSD fluctuations of
Figure 1. The predicted structural models of the ABL-T315I and EGFR-T790M mutants. (A) Superposition of the predicted structural
model of the ABL-T315I mutant (in blue) with the crystal structure of ABL-T315I (active form, pdb entry 2Z60, in green). (B) Superposition of the
predicted structural model of the EGFR-T790M mutant (in blue) with the crystal structure of EGFR-T790M (active form, pdb entry 2JIT, in green). The
initial ABL and EGFR structures that converged during homology modeling refinement to the crystallographic active conformations of the mutants
correspond to the Src-like inactive ABL (pdb entry 2G1T) and Src-like inactive EGFR (pdb entry 2GS7).
doi:10.1371/journal.pcbi.1000487.g001
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displayed a similar convergence to an equilibrium plateau within
first 2 ns–3 ns and remained stable for the remainder of
simulations. Characteristically, mutations can induce larger
thermal fluctuations in the inactive kinase state (RMSD=2.2 A ˚–
2.5 A ˚), especially for ABL-L387M and EGFR-L858R. Overall,
there were no significant differences between the RMSD profiles
of ABL and EGFR in structurally different kinase states, although
thermal fluctuations of the EGFR variants were somewhat smaller
(1.5A ˚–2.0A ˚)( Figures 6,7). We also analyzed protein flexibility
variations computed from the root mean square fluctuation
(RMSF) of the backbone residues. To facilitate the analysis, the
average protein flexibility profiles were mapped onto the
respective conformational states of ABL and EGFR using a
color-coded sliding scheme. In agreement with the structural
factors, the regions of larger thermal fluctuations and the increased
conformational flexibility corresponded to P-loop, aC-helix and
the activation loop. During simulations in the Src-like inactive
states, we observed a consistently increased level of thermal
fluctuations for the ABL-L387M (Figure 4) and EGFR-L858R
mutants (Figure 6) that are strategically located in the middle of
the activation loop and may thus cause larger local perturbations.
In contrast, EGFR-L858R mutant displayed the decreased
thermal fluctuations and smaller RMSF values in the active state
(Figure 7). This may partly reflect the activating nature of the
EGFR-L858R mutation that is known to shift the thermodynamic
equilibrium away from the Src/Cdk-like form towards a more
stable active kinase structure.
Analysis of the time-dependent RMSD and RMSF fluctuations
could provide only an initial and largely qualitative outlook of
potential protein stability changes that may be induced by
mutations. The thermodynamic effect of activating mutations
could be quantified more rigorously when the results of
equilibrium MD simulations are combined with the MM-GBSA
analysis of protein stability change (Figure 8). Coupling between
rigid and flexible regions of a protein and correlation of various
motions may generally lead to both increases and decreases in
thermodynamic stability. Our analysis demonstrated a moderate
decrease in the thermodynamic stability for ABL-T315I and a
more significant effect of ABL-L387M on the Src-like, inactive
structure (Table 1). The detrimental energetic effect of ABL-
T315I on the inactive structure was due to loss of the molecular
mechanics energy, and specifically its electrostatic component.
The ABL-L387M mutation could lead to a considerable decrease
in the favorable van der Waals interactions as well as concurrent
unfavorable changes in solvation free energy (Table 1,
Figure 8A). In contrast, both activating mutations may
appreciably stabilize the active form of ABL (Table 1). All free
energy components appeared to act concertedly to enhance the
thermodynamic stability of the active form. In particular, the van
der Waals interactions were strengthened in the active form of
ABL-T315I, partly owing to a favorable packing of I315 with the
Met290 and Leu301 residues from the hydrophobic spine. The
results of simulations provided an interesting rationale to the
previously proposed structural effect of the L387M mutation on
kinase activity [18]. This hydrophobic residue is solvent-exposed
Figure 2. The predicted structural models and interactions of the EGFR-L858R mutant. (A) Superposition of the crystal structures for the
inactive EGFR-WT structure (initial structure in homology refinement) (pdb entry 2GS7, in green), EGFR-L858R mutant crystal structure (target
structure in homology refinement) (pdb entry 2ITT, in blue) and computationally predicted EGFR-L858R model (in red). (B) A close-up comparison
between activation loop conformations in the crystal structures of inactive EGFR-WT (pdb entry 2J6M, in green), EGFR-L858R mutant crystal structure
(pdb entry 2ITT, in blue) and the predicted mutant conformation (in red). The lowest energy mutant model is within RMSD=1.98 A ˚ from the crystal
structure of EGFR-L858R. (C) A close-up of functionally important residues and key interactions stabilizing the active conformation of EGFR-L858R. The
ion pairs between Lys-745 and Glu-762 are shown for the crystal structure of the EGFR-L8585R (in blue) and the predicted mutant conformation (in
red).
doi:10.1371/journal.pcbi.1000487.g002
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interface between aC-helix, the N-lobe, and the activation loop in
the Src-like inactive structure (Figure S1). According to the
original conjecture by Kuriyan and coworkers, functional effect of
the activating ABL-L387M may be explained if the Src-like
inactive conformation could represent a significant population of
the inactive ABL states during thermodynamic equilibrium [18].
Our simulations allowed a quantitative insight that supported this
hypothesis. Indeed, local adjustments of the activation loop at the
mutational site may not rescue the weakening packing interactions
caused by L387M in the Src-like structure, and thus could lead to
an appreciable decrease in the thermodynamic stability. At the
same time, ABL-L387M enhanced the thermodynamic stability of
the active kinase state (Table 1, Figure 8A).
Similar effects could be observed from the protein stability
analysis of EGFR mutations (Table 2, Figure 8B). In this case,
both EGFR-T790M and EGFR-L858R induced a detrimental
effect on the Src/Cdk-like inactive state through the decreased
electrostatic and van der Waals interactions, which could not be
offset by the opposing changes in solvation free energy (Table 2).
A greater local mobility induced by mutations in the Src-like
inactive structure was reflected in rather moderate net contribu-
tions of the vibrational entropy and solvation energy. Importantly,
we found that a more significant loss of thermodynamic stability in
the Src-like inactive form may be caused by ABL-L387M and
EGFR-L858R mutations in the activation loop (Tables 1,2). In
contrast, both EGFR mutants may lead to the enhanced
thermodynamic stability of the active structure. The crystal
structure analysis previously indicated that EGFR-L858R may
be incompatible with the local hydrophobic environment in the
Src/Cdk inactive structure [24]. In agreement with the structural
data and the original conjecture proposed by Kuriyan and
colleagues, we determined that mutations with the higher
oncogenic activity, such as a frequently occurring in lung cancer
EGFR-L858R, may induce the greater differential effect on
thermodynamic stability of the inactive and active kinase forms.
We found that the thermodynamic effect of activating mutations in
ABL and EGFR may lead to simultaneous destabilization of the
inactive kinase and the enhanced stability of the active state.
Collectively, these energetic factors may serve as thermodynamic
Figure 3. MD simulations of the ABL kinase domain in the imatinib-bound inactive form. Upper Panel: (A) The RMSD fluctuations of Ca
atoms and (B) the RMSF values of Ca atoms from MD simulations of ABL-WT (in blue), ABL-T315I (in red), and ABL-L387M (in green). MD simulations
were performed using the Imatinib-bound, inactive form of the ABL kinase domain. Legends inside the figure panels refer to the pdb entries used in
MD simulations. The color-coded sliding scheme corresponds to the following ranges of protein flexibility values: red (highly flexible with +5.00
values), brown (+4.00 values), yellow (+3.00), green (+2.00), cyan (+1.00) and blue (the least flexible). Lower Panel: Color-coded mapping of the
averaged protein flexibility profiles (RMSF values) from MD simulations of the ABL-WT and ABL mutants. This mapping is presented for ABL-WT (C),
ABL-T315I (D) and ABL-L387M (E). The color-coded sliding scheme corresponds to the following ranges of protein flexibility values: red (highly flexible
with +5.00 values), brown (+4.00 values), yellow (+3.00), green (+2.00), cyan (+1.00) and blue (the least flexible).
doi:10.1371/journal.pcbi.1000487.g003
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shift in the equilibrium towards the active kinase form. The
computed protein stability changes, caused by cancer mutations,
typically tend to overestimate the absolute value of thermody-
namic variations, due to the inherent nature of large compensating
contributions involved in the MM-GBSA analysis. Nevertheless,
our analysis allowed to reconcile the experimental data and
quantified the differential thermodynamic effect of mutations on
the inactive and active kinase forms.
It is worth noting that activating mutations may induce not only
local protein adjustments near the mutational site, but also cause
allosteric changes in the aC-helix and N-terminal lobe. However,
conformational plasticity of the kinase domain allowed to preserve
structural integrity of the kinase conformational forms. These
results agreed with the NMR studies, in which inactive ABL
conformations were found to exhibit nanosecond backbone
flexibility within the activation loop, yet the conformational
ensemble on average could still closely conform to the crystal
structure [57]. To probe a possibility of observing direct
conformational transitions between the inactive and active kinase
forms, we extended the time scale of MD simulations, but the
observed profile of thermal fluctuations remained qualitatively the
same. The recent NMR analysis [57] indicated that the
microsecond to millisecond time scales associated with the
activation loop motions may enable conformational transitions
between alternative kinase conformations. Hence, computationally
feasible time scales of MD simulations may not be sufficient to
directly observe functionally important conformational transitions
between structurally different kinase forms.
MD Simulations of the ABL and EGFR Regulatory
Complexes
Although ABL and EGFR share a common kinase domain, they
can be regulated through different mechanisms. Indeed, activation
of the ABLkinases canbe linkedwith the formationofmulti-protein
regulatory complexes with the SH2 and SH3 domains [13,17],
whereas EGFR may be activated through dimerization mechanism
[24].Theseregulatoryinteractionshaveamajorrole indetermining
the conformational dynamics of the kinase domain and activation
mechanisms. Crystallographic studies [13,17] demonstrated that
the ABL regulatory complex in the downregulated, inactive can
form a tightly assembled conformation in which the SH3-SH2 unit
docked onto the back of the kinase domain, considerably restricting
its conformational flexibility (Figure 9). Moreover, a critical N-
Figure 4. MD simulations of the ABL kinase domain in the Src-like inactive form. Upper Panel: (A) The RMSD fluctuations of Ca atoms
and (B) the RMSF values of Ca atoms from MD simulations of ABL-WT (in blue), ABL-T315I (in red), and ABL-L387M (in green). MD simulations were
performed using the Src-like inactive form of the ABL kinase domain. Legends inside the figure panels refer to the pdb entries used in MD
simulations. Lower Panel: Color-coded mapping of the averaged protein flexibility profiles (RMSF values) from MD simulations of the ABL-WT and
ABL mutants. This mapping is presented for ABL-WT (C), ABL-T315I (D) and ABL-L387M (E). The color-coded sliding scheme is the same as was
adopted for Figure 3.
doi:10.1371/journal.pcbi.1000487.g004
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domain contributed to the stability of the inactive ABL state (pdb
entry 2FO0) [89,90]. Small angle X-ray scattering (SAXS) analysis
of the activated ABL form revealed that the release of the inhibitory
interactions could allow the SH2 and SH3 domains to switch to a
vastly different structural arrangement [17]. In this structure
(Figure 10), the SH2 domain was docked directly on the top of
the N-lobe (‘‘top-hat’’ conformation) (pdb entry 1OPL), while the
SH3 domain became disordered along with the linker connecting
the SH2 and the kinase domains. To gain dynamic and mechanistic
insight into allosteric effects of the ABL-T315I mutant, we
performed MD simulations of the ABL-SH2-SH3 regulatory
complexes in the inactive (‘‘side-to-side’’) and active (‘‘top-hat’’)
states. The objectives of these simulations were the following: (a) to
determine the effect of activated ABL-T315I mutation on the
conformational dynamics in different functional states of ABL; (b) to
test a hypothesis whether upregulation of kinase activity, caused by
ABL-T315I, may be related to the dynamic preferences in the ‘‘top-
hat’’ conformation of the ABL-SH2-SH3 complex. The results of
simulations were analyzed using a directcomparison with the recent
HX MS experiments of ABL regulatory complexes in the normal
and mutational forms [58].
A distinct pattern of structural flexibility upon T315I mutation
was found from simulations in the inactive ABL state (Figure 9).
The ABL-T315I mutant exhibited a considerably higher degree of
thermal fluctuations as compared to the ABL-WT. The RMSD
profile of ABL-WT in this downregulated form displayed minor
deviations of ,2A ˚ for most of the 20 ns trajectory, suggesting that
ABL-WT could be dynamically very stable in the inactive form. In
contrast, ABL-T315I caused the increasing thermal perturbations
on a longer time scale (after first 12 ns), suggesting a considerable
structural rearrangement of the regulatory complex upon
activating mutation. The RMSF profile revealed the regions of
higher flexibility, including the RT-loop (residues 89–107), aC-
helix (residues 281–291), activation loop (especially in the region of
residues 383–402), and the a-helix at C-terminus (residues 502–
512), the linker region (residues 209–237) and the N-cap (residues
45–66). Our results demonstrated an excellent agreement with the
HX-MS experiments [58], since precisely these structural regions
exhibited a higher exposure to solvent and conformational
mobility evidenced by higher deuterium exchange. Also in
agreement with the experiments, the least mobile regions were
the bundle of a-helices in the large lobe of the ABL kinase domain
and the SH2 domain itself (Figure 9).
Figure 5. MD simulations of the ABL kinase domain in the active form. Upper Panel: (A) The RMSD fluctuations of Ca atoms and (B) the
RMSF values of Ca atoms from MD simulations of ABL-WT (in blue), ABL-T315I (in red), and ABL-L387M (in green). MD simulations were performed
using the active form of the ABL kinase domain. Legends inside the figure panels refer to the pdb entries used in MD simulations. Lower Panel:
Color-coded mapping of the averaged protein flexibility profiles (RMSF values) from MD simulations of the ABL-WT and ABL mutants. This mapping is
presented for ABL-WT (C), ABL-T315I (D) and ABL-L387M (E). The color-coded sliding scheme is the same as was adopted for Figure 3.
doi:10.1371/journal.pcbi.1000487.g005
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dynamic changes in residues 255–275 and 285–300 (near ATP
binding site) as well as allosteric effects that could occur in the
distant RT-loop of the SH3 domain (residues 89–107). The RMSF
profiles of ABL-T315I showed the increased conformational
fluctuations of these regions in the inactive state (Figure 9). In
agreement with the experiment, the altered dynamics of residues
287–302 can impact the stability of the hydrophobic spine. Hence,
this local effect might potentially trigger a shift in equilibrium
towards the active, ‘‘top-hat’’ conformation of the regulatory
complex. Of particular importance were also the observed
dynamic changes at the allosteric site of the RT-loop (Figure 9).
In accordance with the experimental analysis, this region could be
less structurally organized in ABL-T315I, whereby altered
dynamics of the regulatory SH3 domain may ultimately lead to
the increased kinase activity of the mutant. In contrast, simulations
of the ABL complexes in the active, ’’top-hat’’ form showed a
reverse trend, i.e. the increased thermal fluctuations and the
increase flexibility of ABL-WT as compared to the ABL-T315I
mutant (Figure 10). Indeed, mutant complex revealed consider-
ably smaller protein fluctuations in functionally important regions,
especially in the activation loop region (residues 380–400) and in
the ATP binding region (Figure 10). Hence, the activating
mutation may shift dynamic preferences of the regulatory complex
towards the active conformation. Collectively, these findings
corroborated and reconciled the HX MS experimental data
[58], indicating that a subtle impact of the ABL-T315I mutation
could result not only in the localized conformational disturbances
near the immediate site of mutation (region 287–302), but also
influence protein flexibility in distant regions, including the SH3
domain (RT-loop residues 89–107). These dynamic alterations in
the kinase domain and RT-loop may serve as important
mechanistic triggers facilitating thermodynamic stabilization of
the ‘‘top-hat’’ active state. Multiscale simulations of allosteric
communications in the ABL regulatory complexes would be
required to provide further insights into molecular basis of kinase
activation.
Crystallographic and functional studies of EGFR activation
mechanismshaveshownthattheEGFRkinasedomainisintrinsically
autoinhibited, and an intermolecular interaction in the asymmetric
dimer can promote its activation [24]. In contrast, the symmetric
dimer with two kinase domains interacting through a ‘‘head-to-tail’’
arrangement proved to be irrelevant for EGFR activation [24].
Recent MD simulations of the asymmetric EGFR dimer have
Figure 6. MD simulations of the EGFR kinase domain in the Src/Cdk-like inactive form. Upper Panel: (A) The RMSD fluctuations of Ca
atoms and (B) the RMSF values of Ca atoms from MD simulations of EGFR-WT (in blue), EGFR-T790M (in red), and EGFR-L858R (in green). MD
simulations were performed using the Src/Cdk-like inactive form of the EGFR kinase domain. Legends inside the figure panels refer to the pdb entries
used in MD simulations. Lower panel: Color-coded mapping of the averaged protein flexibility profiles (RMSF values) from MD simulations of the
EGFR-WT and EGFR mutants. This mapping is presented for EGFR-WT (C), EGFR-T790M (D) and EGFR-L858R (E). The color-coded sliding scheme is the
same as was adopted for Figure 3.
doi:10.1371/journal.pcbi.1000487.g006
Computational Modeling of Protein Kinases
PLoS Computational Biology | www.ploscompbiol.org 9 August 2009 | Volume 5 | Issue 8 | e1000487confirmed a ‘‘positive’’ effect of activating mutations in stabilizing key
structural elements associated with EGFR dimerization [71]. To
complement this computational study, we sought to investigate a
potential ‘‘negative’’ impact of the activating mutation on confor-
mational dynamics in the symmetric dimer form. We proposed that
the activating mutation may induce considerable perturbations in the
symmetric dimer, since this structure appeared to be incompatible
with the EGFR activation mechanism. Indeed, a comparison of the
RMSD profiles indicated that EGFR-WT could become stable early
(after ,6 ns), followed by minor thermal fluctuations in a narrow
range throughput the simulation period. In contrast, RMSD values
for EGFR-T790M steadily increased in the course of simulations and
beyond 20 ns (Figure S4). These results suggested that the activating
mutation could induce a significant structural reorganization in the
symmetric dimer, as this structure may not be important for the
activation process. Analysis of the RMSF profiles further strength-
ened these arguments as EGFR-T790M showed a higher degree of
structural fluctuation in the activation loop (residue 865–875). The
second region of high conformational mobility corresponded to a-
helix at the C-terminal part of the two monomers (residues 916–930),
which was also more flexible in the mutant. A more systematic
analysis of allosteric transitions during EGFR activation would
require not only further computational efforts but also complemen-
tary structural and functional insights into the impact of specific
activating mutations. This analysis extends beyond the scope of this
manuscript and will be presented elsewhere.
Targeted Molecular Dynamics Simulations of the ABL and
EGFR Kinase Domains
In the current study, TMD simulations of the ABL and EGFR
kinase domains were used symbiotically with other computational
approaches to systematically address both thermodynamic and
mechanistic aspects of kinase activation and compare these effects
between normal and oncogenic kinase forms. We pursued the
following specific objectives: (a) to determine whether conforma-
tional transitions of the activation loop could bring about collective
motions in other functionally important kinase regions that may
serve as mechanistic ‘‘wheels’’ of activation; (b) to determine
similarities and differences between activation pathways in the
ABL and EGFR kinase domains; (c) to propose a mechanistic
model of the activation mechanism and determine molecular
catalysts of ABL and EGFR activation.
The RMSD profiles obtained from TMD simulations of the ABL
(Figure 11A) and EGFR kinase domain (Figure 11 C) revealed
characteristic trends in the nature of activation conformational
transitions. In all cases, we observed a first transition, reflected in a
rapid increase of RMSD values after 2–4 ns, gradual RMSDincrease
in the next 4–5 ns, followed by a second transition and attainment of
Figure 7. MD simulations of the EGFR kinase domain in the active form. Upper Panel: (A) The RMSD fluctuations of Ca atoms and (B) the
RMSF values of Ca atoms from MD simulations of EGFR-WT (in blue), EGFR-T790M (in red), and EGFR-L858R (in green). MD simulations were
performed using the active form of the EGFR kinase domain. Legends inside the figure panels refer to the pdb entries used in MD simulations. Lower
Panel: Color-coded mapping of the averaged protein flexibility profiles (RMSF values) from MD simulations of the EGFR-WT and EGFR mutants. This
mapping is presented for EGFR-WT (C), EGFR-T790M (D) and EGFR-L858R (E). The color-coded sliding scheme is the same as was adopted for Figure 3.
doi:10.1371/journal.pcbi.1000487.g007
Computational Modeling of Protein Kinases
PLoS Computational Biology | www.ploscompbiol.org 10 August 2009 | Volume 5 | Issue 8 | e1000487the target active structure. The RMSD profiles of ABL-T315I and
EGFR-T790M mutants exhibited a sharper first transition, relative to
ABL-WT, followed by a second transition occurring at the onset of
4n s – 5n s( Figure 11 A,C). More pronounced were the differences
detected in the RMSD profile of the activation loop mutants ABL-
L387 and EGFR-L858R, revealing characteristic ‘‘first-order-like’’
transitions (Figure 11 A,C). The RMSF profiles displayed a greater
mobility of the P-loop, aC-helix and the activation loop as compared
to other kinase regions (Figure 11 B, D). It is worth noting that the
steering force was applied only to the activation loop residues, so that
other kinase regions could move freely to accommodate to the
progressive conformational changes. In general, RMSF fluctuations
of the activation loop and aC-helix regions were similar between WT
and mutant kinases, with the noticeable exception of EGFR-L858R
revealing a considerably greater degree of mobility (Figure 11 C,D).
Overall, the RMSF profiles showed appreciable aC-helix fluctuations
(with RMSF .2A ˚) in response to the conformational changes in the
activation loop, suggesting that collective motions of these kinase
regions may play a mechanistic role in the activation process.
Structural and energetic aspects of the activation process were
analyzed by monitoring crucial structural elements of the activation
process, i.e. the dynamic assembly of the hydrophobic spine and the
Figure 8. The protein stability analysis of the ABL and EGFR cancer mutants. Left Panel (A): The computed protein stability changes
between ABL-WT and ABL-T315I, ABL-L387M mutants in the Src-like inactive and active states of ABL. Right Panel (B): The computed protein
stability changes upon EGFR-T790M, EGFR-L858R mutants in the Src/Cdk-like inactive and active states of EGFR. In both panels, a negative value in
the protein stability difference between the WT kinase and a respective mutant corresponds to a destabilization effect of the mutant.
doi:10.1371/journal.pcbi.1000487.g008
Table 1. MM-GBSA calculations of the protein stability for the ABL kinase*.
Energy WT(I) T315I(I) L387M(I) WT(A) T315I(A) L387M(A)
Eele 27874.34 27839.11 27935.50 27940.54 27948.96 27880.00
Evdw 21595.93 21592.86 21560.10 21548.94 21568.18 21559.64
Eint 3028.50 3032.25 3045.91 3040.95 3043.89 3037.51
Egas 26441.77 26399.72 26449.69 26448.44 26473.25 26402.13
Ggbnb 102.98 104.05 99.95 103.75 100.10 102.57
Ggbele 23409.06 23435.75 23369.63 23389.31 23383.73 23460.25
Ggbtot 23306.07 23331.70 23269.69 23285.57 23283.63 23357.68
TStrans 17.06 17.06 17.06 17.06 17.06 17.06
TSrot 17.61 17.61 17.61 17.60 17.57 17.59
TSvib 3167.18 3173.00 3169.09 3166.58 3163.65 3160.37
TStotal 3201.86 3207.67 3203.76 3201.24 3198.29 3195.03
*The columns 2–4 represent the protein stability contributions calculated for the Src-like inactive form of ABL for the WT, T3135I and L387M mutants. The columns 5–7
represent the respective protein stability contributions calculated in the active form of ABL for the WT, T315I and L387M mutants. All energies are in Kcal/mol. The
contributions of the free energies are defined in the Materials and Methods section.
doi:10.1371/journal.pcbi.1000487.t001
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PLoS Computational Biology | www.ploscompbiol.org 11 August 2009 | Volume 5 | Issue 8 | e1000487Figure 9. MD simulations of the ABL-SH2-SH3 regulatory complex in the inactive Form. Upper Panel: Color-coded mapping of the
averaged protein flexibility profiles (RMSF values) from MD simulations in the inactive form (pdb entry 2FO0). The mapping is presented for ABL-WT
(A) and ABL-T315I (B). The color-coded sliding scheme is the same as was adopted for Figure 3. Lower Panel: The RMSD fluctuations of Ca Atoms (C)
and the RMSF values of Ca Atoms (D) from MD simulations. MD simulations of ABL-WT (in blue), and ABL-T315I (in red) were performed using the
downregulated inactive ABL form (‘‘side-to-side’’) (pdb entry 2FO0).
doi:10.1371/journal.pcbi.1000487.g009
Table 2. MM-GBSA calculations of the protein stability for the EGFR kinase*.
Energy WT(I) T790M(I) L858R(I) WT(A) T790M(A) L858R(A)
Eele 26408.32 26310.38 26351.15 26502.31 26556.92 26548.48
Evdw 21687.45 21641.53 21657.98 21712.21 21679.19 21670.60
Eint 3172.4 3152.16 3159.98 3135.95 3146.32 3162.52
Egas 24923.32 24799.76 24849.15 25078.57 25089.79 25056.56
Ggbnb 105.03 101.13 98.60 115.97 101.66 97.58
Ggbele 23531.67 23638.02 23576.44 23547.51 23545.82 23572.07
Ggbtot 23426.64 23536.89 23477.83 23431.54 23444.16 23474.49
TStrans 17.07 17.07 17.07 17.14 17.07 17.07
TSrot 17.59 17.58 17.58 17.75 17.59 17.59
TSvib 3204.19 3205.19 3207.81 3226.80 3224.80 3232.91
TStotal 3238.85 3239.84 3242.45 3261.68 3259.46 3267.57
*The columns 2–4 represent the protein stability contributions calculated for the Src/Cdk-like inactive form of EGFR for the WT, T790M and L858R mutants. The columns
5–7 represent the respective protein stability contributions calculated in the active form of EGFR for the WT, T790M and 858R mutants. All energies are in Kcal/mol. The
contributions of the free energies are defined in the Materials and Methods section.
doi:10.1371/journal.pcbi.1000487.t002
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regulation. The analysis of TMD simulations for ABL and EGFR
mutants provided evidence of a common multi-stage activation
process that could involve cooperative transitions between different
conformational states of the kinase domain (Figures 12). Here, we
detail the characteristic stages of the activation pathways by
dissecting the results of TMD simulations for ABL mutants. At
the first stage, modest fluctuations of the K271-E286 salt bridge, an
important structural attribute of the Imatinib-bound ABL inactive
state, were accompanied by a first sharp transition and an abrupt
decrease of the E286-R386 distances (at the onset of ,4 ns)
(Figure 12A,B). The first transitioncould be determined by a rapid
and cooperative assembly of the hydrophobic spine,which maybe a
common mechanistic event, shared by ABL and EGFR kinases
(Figures 13,14). In particular, structural consolidation of the
hydrophobic spine residues in ABL (Met290, Leu301, His361, and
Phe382) may serve as a mechanistic ‘‘trigger’’ of the activation
process to catalyze subsequent rearrangement of the K271-E286
and E286-R386 pairs in ABL-T315I and ABL-L387M mutants.
The second transition could be prompted by the further
consolidation of the hydrophobic spine, a concerted and sharp
breakage of the K271-E286 salt bridge (loss of the Imatinib-bound
inactive structure) and a concomitant formation of the E286-R386
ion pair (Figure 12A,B). These events could collectively signify the
formation of the Src-like structure. At the final stage, a concerted
breakage of the E286-R386 ion pair and reformation of the K271-
E286 salt bridge signaled the completion of the conformational
transition and stabilization of the active ABL form. These energetic
changes may reflect concerted structural motions of the activation
loop and aC-helix that could collectively serve as mechanistic
wheels of the activation transitions (Figures 13,14).
Structural Analysis of Activation Pathways in the ABL and
EGFR Kinase Domains
We analyzed mechanistic features of the ABL/EGFR activation
pathways that suggested interesting universal aspects of the
activation mechanism (Figure S5). We detail this analysis by
highlighting crucial elements of ABL conformational transitions.
Initially, the ‘‘upper’’ part of the activation loop (residues 379–383)
remained relatively stable and unperturbed by the activation
process (Figure S5, upper panel). At the same time the ‘‘middle’’
region of the activation loop (residues 384–391) began to unfold
towards a more open conformation. In particular, the kinase
residues 384–387 moved closer to the P-loop. As a result, the
distance between Arg386 (activation loop) and Glu 255 (P-loop)
decreased and then started increasing as the activation loop moved
towards the intermediate Src-like inactive conformation. The
middle segment (residues 387–391) led the transition of the
activation loop towards the Src-like intermediate state. This process
Figure 10. MD simulations of the ABL-SH2-SH3 regulatory complex in the active form. Upper Panel: Color-coded mapping of the
averaged protein flexibility profiles (RMSF values) from MD simulations in the active form (pdb entry 1OPL). The mapping is presented for ABL-WT (A)
and ABL-T315I (B). The color-coded sliding scheme is the same as was adopted for Figure 3. Lower Panel: The RMSD fluctuations of Ca Atoms (C)
and the RMSF values of Ca Atoms (D) from MD simulations. MD simulations of ABL-WT (in blue), and ABL-T315I (in red) were performed using the
active ABL form (‘‘top-hat’’) (pdb entry 1OPL).
doi:10.1371/journal.pcbi.1000487.g010
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lower end of the activation loop (residues 394–400). The activation
loop continued its movement towards the Src-like inactive
conformation by pushing aC-helix away from the active site to
allow itself a sufficient room between aC-helix and the catalytic
loop, while the P-loop came in to fill the created gap (Figure S5).
Importantly, we found a high degree of similarity between a
meta-stable TMD intermediate and the Src-like crystal structure
(Figure S6). The main structural features of the Src-like ABL
conformation were reproduced in the TMD intermediate state. In
this conformation, aC-helix was rotated and moved out of the
active site (aC-helix-Glu-out position), the DFG motif flipped in
the intermediate DFG-in position, the anti-parallel b-sheet from
the lower part of the activation loop unfolded and the P-loop
moved in towards the active site (Figure S6). These structural
changes were accompanied by a concerted breakage of the K271-
E286 ion pair and formation of the E286-R386 salt bridge. Hence,
the molecular mechanism of ABL activation by cancer mutations
may favor stabilization of the Src-like structure.
Mechanistic Catalysts of the EGFR Kinase Domain
Activation
The EGFR-L858R mutation is recognized for its frequent
occurrence and high oncogenic activity and may arguably have a
more drastic effect on the activation mechanism. Indeed, what
attracted our attention in the analysis of TMD simulations was a
pronounced, ‘‘first-order’’-like transition in EGFR L858R at the
onset of 4 ns. At this point K745-E762 and E762-R858 distances
sharply decreased and respective pairs came considerably closer,
yet none of these ion pairs was fully formed (Figure 12D).
Intrigued by this observation, we inspected the representative
conformations immediately preceding and following this drastic
transition, in order to gain structural insight into the nature of
meta-stable intermediates. A considerable conformational change
and formation of a meta-stable intermediate was coordinated by
repositioning of the aC-helix towards the active-like state. Hence,
EGFR-L858R may facilitate the activation process through
coordinated assembly of the hydrophobic spine and movements
of aC-helix toward the active-like position. While the hydrophobic
spine seemed to be established at the transition state conforma-
tions, the K745-E762 salt bridge was already broken and the
E762-R858 ion pair was not yet formed . During a second
coordinated transition to the active kinase form, we detected a
concerted formation of the K745-E762 salt bridge and a
simultaneous disengagement of the E762-R858 pair (Figure 12D).
Hence, consolidation of the hydrophobic spine and formation of
the K745-E762 salt bridge are main characteristics of both normal
and oncogenic EGFR forms, as was previously suggested. A
cooperative ‘‘mechanical lock’’ staples the gatekeeper T790
residue with the hydrophobic spine in the EGFR kinase domain
Figure 11. TMD simulations of the ABL and EGFR kinase domains. Time-dependent RMSD profile of Ca atoms obtained from TMD
simulations of ABL (A) and EGFR kinase domains (C). The RMSF values of Ca atoms obtained from TMD simulations of ABL (B) and EGFR kinase
domains (D). ABL-WT/EGFR-WT (in blue), ABL-T315I/EGFR-T790M (in red), and ABL-L387M/EGFR-L858R (in green). Legends inside the figure panels
refer to the pdb entries corresponding to MD simulations from different conformational states of the kinase domain.
doi:10.1371/journal.pcbi.1000487.g011
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consolidation of the hydrophobic spine and formation of the
K745-E762 salt bridge are main characteristics of both normal
and oncogenic EGFR forms, as was previously suggested [71].
Importantly, our analysis, which is based on sufficiently longer
TMD simulations, revealed a different and more subtle mecha-
nistic role of these structural catalysts in the activation process.
Indeed, a rapid formation of the hydrophobic spine corresponded
to the early first sharp transition and may serve as a key structural
‘‘trigger’’ of the activation process that is accelerated by the
mutation. Subsequently, strengthening of the K745-E762 salt
bridge that occurred at the late stage of the reaction may function
as the structural ‘‘consolidator’’ sealing a complete assembly of the
active kinase form. Combining thermodynamic and mechanistic
insights, we could suggest that a pronounced effect of EGFR-
L858R on the activation process may partly explain the unusually
high oncogenic activity and frequent occurrence of L858R in lung
cancer and a high oncogenic activity of the T790M/L858R
tandem [50]. These results corroborated with our previous
insights, suggesting that cancer mutations may have a similar
mechanism of activation, yet mutations with the higher oncogenic
activity may have a greater differential impact on thermodynamic
stability of the active and inactive states. Molecular mechanisms of
activation by cancer mutations could mimic the activation process
of the normal kinase, while exploiting conserved structural
catalysts to accelerate a conformational transition and the
enhanced stabilization of the active kinase form.
A rigorous structural and energetic analysis of the transition
state ensemble (TSE) for the activation reaction implies the
determination of the ‘‘true’’ reaction coordinate and computations
of the potential of mean force (PMF) along the respective
activation pathways [67,68]. A comparative analysis of the TSE
for studied systems would require considerable computational
resources and extends beyond the scope of this study. Neverthe-
less, by combining thermodynamic and mechanistic insights
obtained in this study, we could offer a plausible qualitative
rationale of the kinetic factors contributing to the kinase activation.
In particular, we could speculate that the observed structural
assembly of the hydrophobic spine may control energetic
stabilization of the TSE during the activation reaction in both
normal and oncogenic kinase forms. This may effectively lower the
activation barrier for bulkier gatekeeper mutants that could
strengthen their interactions in the TSE with the hydrophobic
regulatory spine. Concurrently, the differential thermodynamic
effect of mutations may destabilize the inactive kinase form and
also contribute to lowering of the activation energy barrier. It is
likely that these factors could collectively enhance kinase activation
by cancer mutations.
Molecular Docking and Differential Sensitivity of EGFR
Inhibitors
Understanding of molecular signatures of activation mecha-
nisms in the normal and oncogenic states may aid in the
Figure 12. Time evolution of characteristic salt bridges in TMD simulations. The time evolution profiles of the formation and breakage of
characteristic salt bridge profiles are shown for ABL-T315I (A), ABL-L387M (B), EGFR-T790M (C) and EGFR-L858R (D).
doi:10.1371/journal.pcbi.1000487.g012
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available crystal structures and experimental dissociation constants
of the EGFR complexes with cancer drugs provided a basis for
computational modeling using molecular docking and binding free
energy simulations. The primary objective of this analysis was to
offer a molecular rationale to the observed differential sensitivity
by which EGFR-T790M and EGFR-L858R mutants confer to
Lapatinib [23], Geftinib, and AEE788 inhibitors [51–53] (Figure
S7). The predicted binding mode of Lapatinib bound to the co-
crystal inactive structure and computed binding affinity were in a
good agreement with the crystal structure (Figure S8A) and
experimental dissociation constant (Table S1). In accordance
with the thermodynamic data, Lapatinib was highly selective
towards the inactive form of the WT EGFR, since the predicted
binding poses with the active EGFR structures resulted in
structural divergence and a concomitant dramatic loss in the
binding free energies (Table S1). Docking of Geftinib with the
EGFR crystal structures predicted binding modes of the inhibitors
within RMSD=1.5 A ˚ from the respective crystal structures
(Figures S8 B). In agreement with the crystallographic data,
docking of AE788 with the spectrum of EGFR structures predicted
virtually identical binding modes of the inhibitor (Figure S8 C).
The predicted binding mode of Geftinib in the EGFR-T790M
crystal structure suggested a molecular evidence for the greater
potency of the inhibitor over EGFR-WT. Indeed, the enhanced
interactions between the aniline ring of Geftinib and the M790
residue side-chain may contribute to the greater potency of this
inhibitor towards the T790M EGFR mutant (Figure S8 D, E).
Indeed, the more favorable halogen-sulfur interactions formed
between Geftinib and M790 in the crystal structure resulted in the
greater potency of this inhibitor, as compared to AEE788, which
was consistent with the experimental data (Figures S8 F, Table
S1). Structural similarity of the inhibitor complexes with the active
forms of EGFR produced respectively similar binding free
energies, as manifested in the binding profile of Geftinib (Table
S1). Hence, the enhanced binding affinity of Geftinib to the
L858R and T790M mutants could be attributed to weaker binding
with the inactive EGFR-WT, rather than to the differences in the
inhibitor binding with the active form of the kinases. These results
suggested that structural preponderance of the active form for the
studied EGFR mutants may be an important driving factor of their
enhanced drug binding.
Figure 13. A mechanistic analysis of the TMD activation pathways for the ABL- T315I and EGFR-T790M gatekeeper mutations. A
dynamic assembly of the hydrophobic spine interactions during the activation process is shown for the ABL-T315I mutant (upper panel) and the
EGFR-T790M mutant (lower panel). The hydrophobic spine of the ABL kinase domain is formed through assembly of the gate-keeper residue with the
Met290, Leu301, His361, and Phe382 residues. The hydrophobic spine of the EGFR kinase domain is similarly formed by linking the gate-keeper
residue with Met766, Leu777, His835, and Phe856 residues respectively. (A) The initial model of ABL-T315I in the inactive form. (B) The characteristic
TMD intermediate of ABL-T315I. (C) The final structure of ABL-T315I in the active form. (D) The initial model of EGFR-T790M in the inactive form. (B)
The characteristic TMD intermediate of EGFR-T790M. (C) The final structure of EGFR-T790M in the active form. The assembled hydrophobic spine is
present in all TMD intermediates. The determined meta-stable ABL intermediate closely resembles the Src-like inactive crystal structure.
doi:10.1371/journal.pcbi.1000487.g013
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This study reconciled current structural and functional data
with the insights from computational approaches, pointing to
general mechanistic aspects of activating transitions in protein
kinases. In particular, the analysis of activation pathways in the
ABL and EGFR kinase domains has revealed common features
that qualitatively agree with the earlier studies of activating
conformational transitions in the Src kinase [64–67] and CDK5
kinase [68]. Interestingly, the formation of Src-like intermediate
structure that may facilitate conformational transitions between
inactive and active kinase forms may be a common feature of
activation mechanism. Indeed, a very similar low-energy interme-
diate conformation was also observed in simulations of CDK5
kinase [68]. The observed similarity in the nature of the
conformational pathways and structural features of the interme-
diate conformations shared in a number of kinases may suggest
functional significance of the proposed activation mechanism in
kinase regulation. The emerging understanding of molecular
signatures, associated with cancer causing mutations in protein
kinases may ultimately help in tracing the effect of genetic
variations responsible for the molecular pathologic ‘lesions’
associated with disease susceptibility.
Although the value of protein structural information in the design
of cancer therapeutics, for which specific mutations arelikely to be the
cause, has been recognized [91,92], structure-based drug design has
rarely exploited such information. Though understanding of the
precise role of genetic alterations in tumorigenesis is challenging,
exploiting personal genomic data may provide a basis for discovery of
cancer drugs targeting a spectrum of mutational changes that occur
in cancer [93,94]. Characterization of the conformational landscape
for the protein kinases and cancer mutants can provide access to
unique conformations that are rarely exploited in biochemical and
structural experiments typically biased towards the active state of the
enzyme. This could facilitate design of kinase inhibitors selectively
targeting kinase activation pathways as well as engineering and
optimizing the clinical effects of existing drugs. Hence, future
computational modeling studies can further inform and facilitate
experiments exploring the molecular pathology of tumorigenesis and
implications in rationale drug design of specific cancer therapies.
Materials and Methods
Structure Preparation
In simulations of the ABL and EGFR kinase domains, we used
the following crystal structures from the Protein Data Bank (PDB):
Figure 14. A mechanistic analysis of the TMD activation pathways for the ABL-L387M and EGFR-L858R mutations. A dynamic
assembly of the hydrophobic spine during TMD simulations is shown for the ABL-L387M mutant (upper panel) and the EGFR-L858R mutant (lower
panel). (A) The initial model of ABL-L387M in the inactive form. (B) The characteristic TMD intermediate of ABL-L387M. (C) The final structure of ABL-
L387M in the active form. (D) The initial model of EGFR-L858R in the inactive form. (B) The characteristic TMD intermediate of EGFR-L858R. (C) The
final structure of EGFR-L858R in the active form. The assembled hydrophobic spine is present in all TMD intermediates.
doi:10.1371/journal.pcbi.1000487.g014
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inactive ABL structure), pdb entry 1M52 (active ABL structure),
pdb entry 1XKK (Src/Cdk-like inactive EGFR structure), pdb
entry 2GS7 (Src/Cdk-like inactive EGFR structure) and pdb entry
2J6M (active EGFR structure). For simulations with the ABL
complexes, we used the crystal structure of the ABL-SH2-SH3
complex in the inactive form (pdb entry 2FO0) and active form
(pdb entry 1OPL). For simulations with the EGFR dimers, we
utilized the crystal structure of the EGFR in the inactive state (pdb
entry 2GS7). All crystallographic water molecules, bound
inhibitors, and other heteroatoms were removed. The residue
range 702–984 was used for the EGFR kinase domain and 225–
498 for the ABL kinase domain. The structure of 1XKK is
unresolved for residues 749–754 (activation loop) and residues
867–876 (aC-helix), thus the unresolved parts were modeled using
the program MODELLER which is an automated approach to
comparative protein structure modeling by satisfaction of spatial
restraints [95,96]. Similarly the active form of ABL (pdb entry
1M52) does not have residues 225–231, so they were also modeled
using the same strategy. All mutations were introduced into the
respective crystal structures of ABL and EGFR using MOD-
ELLER. Local minimization was done to relax the protein
environment surrounding the mutant residue.
Homology Modeling
Homology modeling of the ABL and EGFR mutants was done
using MODELLER [95,96] with a subsequent refinement of side-
chains by the SCRWL3 program [97]. Initial models were built
based on the crystal structures of ABL-WT and EGFR-WT in
inactive, Src-like inactive and active forms. The mutated structures
were initially refined using 5000 steps of minimization to ensure
sufficient relaxation of the local environment near mutational site.
Initial models were built in MODELLER with a flexible sphere of
5A ˚ around mutated residue. We gradually increased the radius of
this sphere in 5 A ˚ steps until the radius reached the 25 A ˚ values
(i.e. all residues falling within this range were treated as flexible). A
protocol involving a conjugate gradient (CG) minimization,
followed by simulated annealing refinement was repeated 20
times to generate 100 initial models for each cancer mutant in this
study. In the optimization stage, we initially used CG minimiza-
tion to remove unfavorable contacts and to optimize geometry.
MD simulations were then run at increasing temperature values
from 150 K to 1500 K, followed by simulated annealing and
sampling at temperatures of 1500 K, 1000 K, 800 K, 600 K,
500 K, 400 K, 320 K, and 300 K respectively. The models were
generated using 20 iterations of this protocol and the predicted
structural model was chosen out of the 100 models as scored by the
MODELLER default scoring function. The final models were
then refined in 2 ns MD simulations using NAMD 2.6 [98] with
the CHARMM27 force field [99,100]and the explicit TIP3P water
model as implemented in NAMD 2.6 [101].
MD Simulations
MD simulations of the ABL kinase domain were independently
launched for ABL-WT, ABL-T315I and ABL-L387M from the
inactive form (pdb entry 1IEP), Src-like structure (pdb entry
2G1T) and active state (pdb entry 1M52). Similarly, MD
simulations of the EGFR kinase domain were initiated for
EGFR-WT, EGFR-T790M, EGFR-L858R from the Src/Cdk-
like inactive structures (pdb entries 1XKK, 2GS7), and active
conformational form (pdb entry 2G6M). We performed a total of
15 MD simulations of the ABL and EGFR kinase domains (each of
10 ns duration) and a total of 4 MD simulations of the ABL and
EGFR complexes (each of 20 ns duration). MD simulations were
carried out using NAMD 2.6 with the CHARMM27 force field
[102,103] and the explicit TIP3P water model widely used in MD
simulations [101]. The details of structure preparation and solvent
models are given in Tables S2 and S3. The VMD program was
used for the preparation and analysis of simulations [102].
The psfgen utility in VMD was employed to generate a protein
structure file. The residue Tyr-393 from the ABL kinase domain
(all structures) and Tyr-869 in the EGFR kinase domain (all
structures) were phosphorylated (22 charge state) using VMD.
Thereafter the structures were solvated in a box of water with the
buffering distance of 15 A ˚; assuming normal charge states of
ionizable groups corresponding to pH 7, sodium (Na
+) and
chloride (Cl
2) counter-ions at physiological concentration of
0.15 mol/L were added to achieve charge neutrality and to
mimic biological environment more closely. All Na
+ and Cl
2 ions
were placed at least 8 A ˚ away from any protein atoms and from
each other. The system was subjected to initial minimization for
10,000 steps keeping protein atoms fixed (minimization of water
molecules) followed by 10,000 steps of minimization keeping only
protein backbone fixed to allow protein side chains to relax. This
was followed by final 10,000 steps of minimization without any
constraints on the system.
Equilibration was done in steps by gradually increasing the
system temperature in steps of 20 K starting from 10 K until
310 K. At each step 10,000 steps equilibration was run while
applying a harmonic restraining force of 10 Kcalmol
21 A ˚ 22 to all
backbone Ca atoms. Thereafter the system was equilibrated for
150,000 steps at 310 K (NVT) and then for further 150,000 steps
at 310 K using Langevin piston (NPT) to maintain the pressure.
Finally the restrains were removed and the system was equilibrated
for 500,000 steps to prepare the system for simulation.
An NPT simulation was run on the equilibrated structure
keeping the temperature at 310 K and pressure at 1 bar using
Langevin piston coupling algorithm. The integration time step of
the simulations was set to 2.0 fs; the SHAKE algorithm was used
to constrain the lengths of all chemical bonds involving hydrogen
atoms at their equilibrium values; and the water geometry was
restrained rigid by using the SETTLE algorithm. Nonbonded van
der Waals interactions were treated by using a switching function
at 10A and reaching zero at a distance of 12 A. The particle-mesh
Ewald algorithm (PME) as implied in NAMD was used to handle
long range electrostatic forces [103]. The entire procedure was
applied to all structures used in this study.
Protein Stability Analysis
Protein stability calculations were done using the molecular
mechanics (MM) AMBER force field [104] and the solvation
energy term based on continuum generalized Born and solvent
accessible surface area (GB/SA) solvation model [105–108]. In
MM-GBSA calculations, we employed AMBER99 force field. The
choice of AMBER99 was made because we used phosphorylated
tyrosine residues in MD simulations (Tyr-393 in ABL and Tyr-869
in EGFR) for which available parameters were derived in the
AMBER94/99 force field. The parameters for phosphorylated
tyrosines were taken from [108].
The total free energy was given as
Gmolecule~GgbtotzEgas{TSsolute
Ggbtot is the solvation free energy; Egas is the molecular mechanical
energy of the molecule summing up the electrostatic Eele
interactions, the van der Waals contributions Evdw and the internal
strain energy Eint. TSsolute is the sum of TStrans, TSrot, and TSvib which
are the translational, rotational and vibrational entropy contribu-
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was determined using the Linear Combinations of Pairwise
Overlaps (LCPO) method where the hydrophobic contribution
to the solvation free energy is determined by the Solvent Accessible
Surface Area (SASA) dependent term. The total solvation free
energy Ggbtot is the sum of nonpolar Ggbnp and polar Ggbele
contributions. The electrostatic contribution to the solvation free
energy Ggbele involves using the GB equation to estimate the
electrostatic contributions to the solvation free energy. We also
carried out normal mode calculations to determine the entropy
contribution to the protein stability changes. Normal mode
analysis involves calculation and diagonalization of a mass-
weighted second derivative matrix. The entropic contribution
was calculated within the AMBER module NMODE, where the
vibrational entropy contribution TSvib was evaluated from classical
statistical mechanics formula. A dielectric constant of 4rij, where rij
is the distance between atoms i and j of the molecule, is used in the
normal mode calculations.
Assuming a two state model for calculation of the free energy
stabilities, we would need to evaluate the difference in energy
between the folded and unfolded WT kinase and compare to the
respective difference in energy between the folded and unfolded
mutant kinase. It is assumed that, in the unfolded state, individual
residues may not interact, and hence the contributions of residues
other than the one under mutation are the same in the WT and
mutant proteins. Hence, protein stability computations for the WT
and mutant kinases could refer to somewhat different unfolded
reference states, which are associated with the free energies of
individual WT and mutated residues in solution. According to our
model, we assumed that this difference could be small compared to
the respective differences between free energies of folded WT and
mutant kinase structures.
Consequently, we have evaluated protein stability changes
induced by mutations in structurally different conformational
forms of ABL and EGFR. A practical implementation of this
approximation involved evaluation of the free energies for 1,000
snapshots selected at 10 ps interval along MD trajectories for the
WT and respective mutant. The total free energy values were
obtained by averaging calculated contributions over 1,000
simulation snapshots. The protein stability changes were then
approximated based on the free energy difference between the
WT and mutant kinase. Free energy evaluations could be
performed using either separate trajectories of the WT and
mutant kinases or a single trajectory of the WT protein, followed
by introducing mutation and local refinement of the individual
snapshots from the WT trajectory [109]. We have used a more
rigorous, yet more computationally intensive separate trajectory
protocol based on independent MD simulations of the WT and
mutant kinases.
TMD Simulations
In TMD simulations, a chosen subset of atoms is steered
towards a target structure, while the other atoms may also move in
response to this structural change. Hence, this approach could
simulate large scale conformational transition in biomolecules
which are otherwise difficult or impossible to realize using
conventional MD simulations. The RMSD between the current
structure and the target structure was used to calculate an
additional steering force in TMD simulations, which was applied
on every atom from the chosen molecular subset, and is calculated
as follows:
UTMD~1=21k=N RMSD t ðÞ {RMSDo t ðÞ ½ 
2
RMSD(t) represents the relative distance for a chosen molecular
subset between the current structure at the simulation time t and
the reference target structure. RMSD0 (t) is the target RMSD
value at simulation time t. The technical details of TMD
simulations setup were similar to equilibrium MD simulations.
The important distinction is presence of the RMSD restraint with
a force constant of 2 Kcalmol
21 A ˚ 22 that was applied to all heavy
atoms in the activation loop. TMD simulations were run for 10 ns
with a time step of 2 fs. The conformational transition from the
initial to the target structure was determined by decreasing the
value of RMSDo (t) as a function of the simulation time. The value
of RMSDo (t) was linearly decreased to 0 A ˚ during the first 2 ns of
TMD, and then kept at zero during the subsequent 10 ns of
equilibration. Upon reaching the target structure, an additional
2 ns allowed to fully relax into the final target structure.
The complete activation loop (residues 379–401 in ABL and
residues 853–878 in EGFR) was a subject of a steering force which
was applied to every atom of this protein region to simulate
conformational transitions between inactive and active kinase
forms. TMD simulations were carried out for ABL-WT, ABL-
T315I and ABL-L387M to model conformational transitions from
the Imatinib-bound, inactive state of ABL (pdb entry 1IEP) to the
target active ABL conformation (pdb entry 1M52 for ABL-WT
and ABL-L387M; pdb entry 2Z60 for ABL-T315I). Similarly,
TMD simulations were carried out for EGFR-WT, EGFR-
T790M and EGFR-L858R to model conformational transitions
between the Src/Cdk-like inactive form of EGFR (pdb entry
1XKK) and the target active EGFR form (pdb entry 2J6M for
EGFR-WT; pdb entry 2JIU for EGFR-T790M; and pdb entry
2ITT for EGFR-L858R). The details of structure preparation for
TMD simulations of the ABL and EGFR kinase domains are given
in Table S2.
Molecular Docking and Binding Free Energy Calculations
Molecular docking simulations of EGFR inhibitors were
performed using replica-exchange Monte Carlo simulations with
the ensembles of multiple protein kinase conformations. The
protein conformational ensembles for the EGFR-WT, EGFR-
T790M and EGFR-L858R were obtained by extracting a total of
1,000 snapshots from MD simulations with different conforma-
tional forms of the EGFR kinase domain. The details of the
docking protocol were documented in details in our previous
studies [110,111].
In brief, we employed the AMBER force field combined with an
implicit solvation model. The dispersion-repulsion and electro-
static terms were modified to include a soft core component that
was originally developed in free energy simulations to remove the
singularity in the potentials and improve numerical stability of the
simulations [112]. Replica-exchange simulations used 1,000
replicas of the system (corresponding to 1,000 different snapshots)
attributed respectively to 1,000 different temperature levels that
were uniformly distributed in the range between 5300 K and
300 K. Monte Carlo moves were performed simultaneously and
independently for each replica at the corresponding temperature
level. A process of swapping configurations was repeated 100 times
after each simulation cycle for all replicas. The inhibitor
conformations and orientations were sampled in a parallelepiped
that encompasses the crystal structures of the inhibitor complexes
with a 10.0 A ˚ cushion added to every side of the box surrounding
the binding interface. The protein kinase conformation was held
fixed in the minimized conformation, while the rigid body degrees
of freedom and the inhibitor rotatable angles were treated as
independent variables during ligand docking.
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inhibitors was calculated using the following expression:
Gbind~Gcomplex{Gprotein{Gligand
Binding free energy evaluations were performed by using the
distribution of 1,000 low-energy complexes obtained from replica-
exchange Monte Carlo docking simulations at T=300 K. The
structures for the uncomplexed kinase and the inhibitor were
generated by separating the protein and inhibitor coordinates,
followed by an additional minimization of the unbound protein
and inhibitor.
Supporting Information
Figure S1 Conformational Landscape of the ABL Kinase
Domain. The crystal structures of ABL represent the following
conformational forms: the Imatinib-bound, inactive structure (pdb
entry 1IEP) (A), the Src-like inactive structure (pdb entry 2G1T)
(B), and the active structure (pdb entry 1M52) (C). A conserved
K271-E286 salt bridge is characteristically present in the Imatinib-
bound inactive structure (D). This salt bridge is broken and
replaced by the E286-R386 ion pair in the Scr-like inactive
structure (E). The K271-E286 ion pair is restored in the active
structure (F). The activation loop in these structures is highlighted
in blue and the activating mutations are denoted by red balls.
Found at: doi:10.1371/journal.pcbi.1000487.s001 (1.97 MB TIF)
Figure S2 Conformational Landscape of the EGFR Kinase
Domain. The crystal structures of EGFR represent the following
conformational forms: the Lapatinib-bound, inactive structure
(pdb entry 1XKK) (A), the Src/Cdk-like inactive structure (pdb
entry 2GS7) (B), and the active structure (pdb entry 2J6M) (C). A
conserved K745-E262 salt bridge is broken in the Src/Cdk-like
inactive structures (D,E). This salt bridge is present in the active
structure (F). The activation loop in these structures is highlighted
in blue and the activating mutations are denoted by red balls.
Found at: doi:10.1371/journal.pcbi.1000487.s002 (2.07 MB TIF)
Figure S3 A Close-up of the Structural Cluster Formed by the
Gatekeeper T315I Mutant and the DFG Motif. (A) Superposition
of the predicted structural cluster between ABL-T315I and DFG
(in blue) with the crystallographic conformation (pdb entry 2Z60,
in green). (B) Superposition of the predicted structural cluster
between EGFR-T790M and DFG (in blue) with the crystallo-
graphic conformation (pdb entry 2JIT, in green) (C) Similarity in
the predicted structure and packing interactions between the DFG
conformation and the gatekeeper residues T315I in ABL (dark
blue) and T790M in EGFR (light blue). Note that the predicted
EGFR-DFG conformation is similar to the one observed in the
second molecule of the EGFR-T790M crystal structure, which
fully overlaps with the predicted model.
Found at: doi:10.1371/journal.pcbi.1000487.s003 (0.44 MB TIF)
Figure S4 MD Simulations of the symmetric EGFR dimer.
Upper Panel: Color-coded mapping of the averaged protein
flexibility profiles (RMSF values) from MD simulations of the
symmetric EGFR dimer (pdb entry 2GS7). The mapping is
presented for EGFR-WT (A) and EGFR-T790M (B). The color-
coded sliding scheme is the same as was adopted for Figure 3.
Lower Panel: The RMSD fluctuations of Ca atoms (C) and the
RMSF values of Ca atoms (D) from MD simulations. MD
simulations of EGFR-WT (in blue), and EGFR-T790M (in red)
were performed using the inactive EGFR dimer (pdb entry 2GS7).
Found at: doi:10.1371/journal.pcbi.1000487.s004 (0.65 MB TIF)
Figure S5 Overview of the TMD Activation Pathways in ABL
Kinase. A mechanistic view of the activation process using
representative snapshots along the activation pathway is shown
on the upper panel for ABL-WT (A), ABL-T315 (B), ABL-L387M
(C), and on the lower panel for EGFR-WT (D), EGFR-T790M
(E), and EGFR-L858R (E). The kinase domain is shown in grey.
The activation loop conformations along activation pathways are
highlighted. Structural changes along the pathway are reflected in
collective motions of the activation loop and aC-helix, serving as
mechanistic ‘‘wheels’’ of the reaction.
Found at: doi:10.1371/journal.pcbi.1000487.s005 (2.05 MB TIF)
Figure S6 Structural similarity between TMD intermediate and
the Src-like crystal structure of ABL. A high similarity is found
between a meta-stable intermediate formed in TMD simulations
of ABL and the Src-like ABL crystal structure. (A) An overlay
between the Imatinib-bound crystal structure of inactive ABL (in
blue) and the Src-like inactive crystal structure of ABL (in red).
Note that the b-sheet formed in the inactive form is broken in the
Src-lime structure. (B) An overlay between the Src-like inactive
crystal structure of ABL (in red) and a meta-stable TMD
intermediate (in yellow). Note that the important structural
features of the Src-like inactive ABL conformation were
reproduced in the TMD intermediate state.
Found at: doi:10.1371/journal.pcbi.1000487.s006 (1.25 MB TIF)
Figure S7 Chemical Structures of Lapatnib, Geftinib and
AE788 Inhibitors.
Found at: doi:10.1371/journal.pcbi.1000487.s007 (0.26 MB TIF)
Figure S8 The Predicted Binding Modes of Lapatinib, Geftinib
and AE788. The crystallographic conformations of Lapatinib (A),
Geftinib (B), and AE788 (C) are shown in default colors (bold,
stick). The crystal structure of the inhibitor is superimposed with
the predicted binding poses docked into the inactive EGFR-WT
(yellow stick), active EGFR-WT (blue stick), EGFR-T790M (light
blue stick) and EGFR-L858R (dark green stick). (D) A close-up of
interactions between Geftinib and T790 in the WT EGFR crystal
structure. (E) A close-up of interactions between Geftinib and
T790 in the WT EGFR crystal structure. (F) A close-up of binding
modes and interactions formed by Geftinib (in s blue) and AE788
(in default colors) in the hydrophobic pocket of the T790M EGFR
mutant. The phenethylamine substituent of AE788 and chlorine-
substituted aniline in Geftinib occupy a similar space in the
hydrophobic pocket of the T790M EGFR mutant.
Found at: doi:10.1371/journal.pcbi.1000487.s008 (1.00 MB TIF)
Table S1 A comparison of the experimental and computed
binding affinities for the EGFR inhibitors.
Found at: doi:10.1371/journal.pcbi.1000487.s009 (0.03 MB
DOC)
Table S2 Structure Preparation Details for MD and TMD
Simulations of the ABL/EGFR Kinase Domains.
Found at: doi:10.1371/journal.pcbi.1000487.s010 (0.03 MB
DOC)
Table S3 Structure Preparation Details for MD Simulations of
the ABL and EGFR Complexes.
Found at: doi:10.1371/journal.pcbi.1000487.s011 (0.03 MB
DOC)
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